Istituto Nazionale dei Tumori

Milan, Lombardy 20133

0 studies enrolling now · 11 studies all time

What they study most

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), Any Solid Tumor, Breast Cancer, Cancer, Colon Cancer, Lymphoma, Non-Hodgkin, Medullary Thyroid Cancer, Melanoma, Metastatic gpNMB Over-expressing Triple Negative Breast Cancer, Neuroblastoma, Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer

Studies at this site

• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study — Running, not enrolling
• A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma — Running, not enrolling
• A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) — Running, not enrolling
• TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations — Running, not enrolling
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma — Completed
• A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma — Completed
• Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation — APPROVED_FOR_MARKETING
• A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma — Stopped early
• CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma — Stopped early
• A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma — Completed
• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer — Completed